» Articles » PMID: 25829142

Selective Estrogen Receptor Modulation Increases Hippocampal Activity During Probabilistic Association Learning in Schizophrenia

Overview
Date 2015 Apr 2
PMID 25829142
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

People with schizophrenia show probabilistic association learning impairment in conjunction with abnormal neural activity. The selective estrogen receptor modulator (SERM) raloxifene preserves neural activity during memory in healthy older men and improves memory in schizophrenia. Here, we tested the extent to which raloxifene modifies neural activity during learning in schizophrenia. Nineteen people with schizophrenia participated in a twelve-week randomized, double-blind, placebo-controlled, cross-over adjunctive treatment trial of the SERM raloxifene administered orally at 120 mg daily to assess brain activity during probabilistic association learning using functional magnetic resonance imaging (fMRI). Raloxifene improved probabilistic association learning and significantly increased fMRI BOLD activity in the hippocampus and parahippocampal gyrus relative to placebo. A separate region of interest confirmatory analysis in 21 patients vs 36 healthy controls showed a positive association between parahippocampal neural activity and learning in patients, but no such relationship in the parahippocampal gyrus of healthy controls. Thus, selective estrogen receptor modulation by raloxifene concurrently increases activity in the parahippocampal gyrus and improves probabilistic association learning in schizophrenia. These results support a role for estrogen receptor modulation of mesial temporal lobe neural activity in the remediation of learning disabilities in both men and women with schizophrenia.

Citing Articles

The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.

Brand B, de Boer J, Marcelis M, Grootens K, Luykx J, Sommer I Schizophr Bull. 2023; 49(6):1579-1590.

PMID: 37116866 PMC: 10686337. DOI: 10.1093/schbul/sbad058.


The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.

Schmidt P, Wei S, Martinez P, Dor R, Guerrieri G, Palladino P Menopause. 2021; 28(4):369-383.

PMID: 33470755 PMC: 9022873. DOI: 10.1097/GME.0000000000001724.


Gaps or links between hormonal therapy and schizophrenia? (Review).

Trifu S, Istrate D, Miruna D Exp Ther Med. 2020; 20(4):3508-3512.

PMID: 32905106 PMC: 7465617. DOI: 10.3892/etm.2020.9017.


Neurobiological mechanisms underlying sex-related differences in stress-related disorders: Effects of neuroactive steroids on the hippocampus.

Hillerer K, Slattery D, Pletzer B Front Neuroendocrinol. 2019; 55:100796.

PMID: 31580837 PMC: 7115954. DOI: 10.1016/j.yfrne.2019.100796.


The Role of Estrogen in Brain and Cognitive Aging.

Russell J, Jones C, Newhouse P Neurotherapeutics. 2019; 16(3):649-665.

PMID: 31364065 PMC: 6694379. DOI: 10.1007/s13311-019-00766-9.


References
1.
Perlman W, Tomaskovic-Crook E, Montague D, Webster M, Rubinow D, Kleinman J . Alteration in estrogen receptor alpha mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol Psychiatry. 2005; 58(10):812-24. DOI: 10.1016/j.biopsych.2005.04.047. View

2.
Wang J, Cheng C, Zhou J, Smith A, Weickert C, Perlman W . Estradiol alters transcription factor gene expression in primate prefrontal cortex. J Neurosci Res. 2004; 76(3):306-14. DOI: 10.1002/jnr.20076. View

3.
Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

4.
Goldstein J, Link B . Gender and the expression of schizophrenia. J Psychiatr Res. 1988; 22(2):141-55. DOI: 10.1016/0022-3956(88)90078-7. View

5.
Sholl S, Kim K . Estrogen receptors in the rhesus monkey brain during fetal development. Brain Res Dev Brain Res. 1989; 50(2):189-96. DOI: 10.1016/0165-3806(89)90194-6. View